Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Liabilities and Shareholders Equity (2016 - 2026)

Protara Therapeutics' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $191.9 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 13.86% to $191.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $703.0 million through Mar 2026, up 28.81% year-over-year, with the annual reading at $209.5 million for FY2025, 15.44% up from the prior year.
  • Liabilities and Shareholders Equity came in at $191.9 million for Q1 2026, down from $209.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $209.5 million in Q4 2025 to a low of $68.1 million in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $144.6 million (2025), against an average of $133.2 million.
  • Year-over-year, Liabilities and Shareholders Equity plummeted 40.46% in 2023 and then surged 147.39% in 2025.
  • Protara Therapeutics' Liabilities and Shareholders Equity stood at $113.3 million in 2022, then plummeted by 30.31% to $79.0 million in 2023, then soared by 129.82% to $181.5 million in 2024, then rose by 15.44% to $209.5 million in 2025, then decreased by 8.38% to $191.9 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Liabilities and Shareholders Equity are $191.9 million (Q1 2026), $209.5 million (Q4 2025), and $144.6 million (Q3 2025).